



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/918,026	07/30/2001	Roseanne M. Crooke	ISPH-0588

26259
LICATA & TYRRELL P.C.
66 E. MAIN STREET
MARLTON, NJ 08053

CONFIRMATION NO. 1035

FORMALITIES LETTER



OC000000006930292

Date Mailed: 10/18/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted


An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 65.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



12-21-01

Sector \$
Box/Seq. #

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0588

Inventors: Crooke et al.

Serial No.: 09/918,026

Filing Date: July 30, 2001

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Title: Antisense Modulation of Acyl CoA
Cholesterol Acyltransferase-2 Expression

"Express Mail" Label No. EV001201193US

Date of Deposit December 18, 2001

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail"
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Assistant Commissioner for Patents, Box Fee
Amendment, Washington, D.C. 20231.

By Kathleen A. Tyrell
Typed Name: Kathleen A. Tyrell, Reg. No. 38,350

BOX MISSING PARTS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

In response to the "Notice to File Missing Parts of
Application--Filing Date Granted" dated **October 18, 2001**, a
response to which is due **December 18, 2001**, enclosed herewith for
filing is:

- 1) The original Combined Declaration and Power of Attorney,
executed by the inventor(s). An unexecuted copy of this
document, attached to the above-identified specification,
was filed by Express Mail No. **EL792267275US** on
July 30, 2001.


- 2) Paper copy of the Sequence Listing;
- 3) Copy of the computer readable form of amended Sequence Listing;
- 4) Amendment under 1.825 directing entry of the Sequence Listing into the application; and
- 5) Statement to Support Filing and Submission in Accordance with 37 CFR 1.821 through 1.825

() Other:

- () An Associate Power of Attorney is also enclosed.
- (XX) Small entity status of this application has been established on July 30, 2001.
- () A Verified Statement Claiming Small Entity Status Under 37 CFR 1.9 and 1.27 has been forwarded to the Refund Section, Accounting Division, Office of Finance on _____. A **copy** of this Verified Statement Claiming Small Entity Status form and the Request for Refund form is enclosed for your convenience.
- () A credit card payment form in the amount of \$_____ is attached to cover the surcharge. Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619.
- (XX) Please charge the surcharge to my Deposit Account No. 50-1619 in the amount of \$65.00.


This sheet is attached in duplicate.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: December 18, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053
(856) 810-1515



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0588
Inventors: Crooke et al.
Serial No.: 09/918,026
Filing Date: July 30, 2001
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: Antisense Modulation of Acyl CoA Cholesterol Acyltransferase Expression

"Express Mail" Label No. EV001201193US
Date of Deposit - December 18, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell

Commissioner for Patents
BOX Missing Parts
United States Patent and Trademark Office
Washington, DC 20231


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- () I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- (XX) I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing submitted herewith.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: December 18, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515